See Retatrutide/Cagrilintide blend dosage trends, reconstitution volumes, and vial size patterns from WPA peptide calculator sessions.
The Retatrutide/Cagrilintide combination pairs a triple receptor agonist (GIP, GLP-1, and glucagon) with a long-acting amylin analog, representing a frontier of metabolic peptide research. This data captures the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting this advanced combination protocol.
There is one fact that has to anchor any honest discussion of the retatrutide/cagrilintide blend: the combination has never been formally studied in a single published clinical trial. There is no shared sponsor program, no IND filing for the pair, no pivotal protocol that has tested the blend at any dose, in any cadence, in any population. The pharmacology rationale that researchers reach for when they decide to stack the two molecules is drawn entirely from two independent programs that share no overlap. , 2023) (338 adults with obesity, 48 weeks, arms at 1 / 4 / 8 / 12mg once weekly with the 12mg arm reaching about 24% mean weight reduction) and the Phase 3 TRIUMPH program from Eli Lilly, which standardized the escalation at 2mg start with 4-week step-ups to 4mg, 8mg, and a 12mg target. 7% mean weight reduction at 68 weeks in REDEFINE 1.
Retatrutide/Cagrilintide is a research-only blend most often sourced for weight-loss and metabolic studies that pair incretin and amylin pharmacology in one protocol — Eli Lilly's investigational triple GIP/GLP-1/glucagon agonist retatrutide alongside Novo Nordisk's amylin analog cagrilintide. No sponsor markets it as a fixed-ratio drug; it ships as lyophilized powder you reconstitute with bacteriostatic water before use.
Retatrutide engages the GIP, GLP-1, and glucagon receptors to amplify glucose-dependent insulin release, slow gastric emptying, and increase resting energy expenditure via the glucagon arm. Cagrilintide engages calcitonin/amylin-receptor heterodimers (AMY1–3) in the area postrema and hypothalamic arcuate nucleus to add a second, independent satiety signal and further slow gastric emptying. The combination is therefore mechanistically complementary rather than redundant.
No randomized clinical trial of the retatrutide + cagrilintide combination has been published. The two molecules are studied separately: retatrutide in the TRIUMPH Phase 3 program for obesity and T2D, and cagrilintide in the REDEFINE Phase 3 program as a fixed combination with semaglutide (CagriSema). Any combined dosing protocol is extrapolated from the individual single-agent data.
Retatrutide/Cagrilintide has a reported half-life of ~6 days (retatrutide-driven), and the dose intervals researchers model most often fall around once weekly. Both components are long-acting (retatrutide ~6 days, cagrilintide ~7–8 days), so once-weekly dosing builds to steady state over about 5 weeks with meaningful carryover between doses. Retatrutide/Cagrilintide is a blend of Cagrilintide and Retatrutide, so a reconstitution figure for it covers the combined vial contents rather than any single component. It is catalogued under Weight Loss on WPA.
186 Retatrutide/Cagrilintide reconstitution calculations have been logged by the WPA community. The most common dose entered is 2mg (38 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 12mg (82 sessions). The most common dosing frequency is once weekly (36 logged protocols), followed by 2x/week (4).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.